Landmark analysis of overall survival (OS) in patients with chronic (CP) or accelerated (AP) phase chronic myeloid leukemia (CML) treated with omacetaxine mepesuccinate.
Meir Wetzler
Consultant or Advisory Role - Teva
Stock Ownership - Teva
Research Funding - Teva
Hagop M. Kantarjian
Research Funding - Teva
Franck E. Nicolini
Consultant or Advisory Role - Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Novartis
Jeffrey Howard Lipton
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Luke Paul Akard
Honoraria - Teva
Michele Baccarani
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Hanna Jean Khoury
Consultant or Advisory Role - Pfizer
Elizabeth Li
Consultant or Advisory Role - PharmaStat
Mihaela C. Munteanu
Employment or Leadership Position - Teva
Stock Ownership - Teva
Jorge E. Cortes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva